Appointment dossier — Renal Sarcoma
Bring this to your appointment. It summarizes what published studies report — it is not medical advice and does not say anything works. Decisions are yours and your care team’s.
Compounds studied in Renal Sarcoma
Compounds named in the cited literature for Renal Sarcoma, labeled by the strongest evidence found:
- partial nephrectomy — Named in the literature
- radiotherapy — Named in the literature
- surgery — Named in the literature
- Wilms' tumor treatment — Named in the literature
Open recruiting trials (18)
- NCT05770037 · Phase 2 / Phase 3 — DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers (United Kingdom)
- NCT07410676 · Phase 1 / Phase 2 — EBNK-001 Allogeneic NK Cells With Low-Dose IL-15 ± Pembrolizumab in Advanced Solid Tumors (China)
- NCT05135975 · Phase 2 — A Study of Cabozantinib as a Maintenance Agent to Prevent Progression or Recurrence in High-Risk Pediatric Solid Tumors (United States)
- NCT06625190 · Phase 1 / Phase 2 — Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors (United States)
- NCT05985161 · Phase 2 — A Study of Selinexor in People With Wilms Tumors and Other Solid Tumors (United States)
- NCT04901702 · Phase 1 / Phase 2 — Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma (United States)
- NCT05969860 · Phase 2 — At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer (United States)
- NCT05732831 · Phase 1 / Phase 2 — Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors (United States)
- NCT05756569 · Phase 2 — Enfortumab Vedotin Plus Pembrolizumab for the Treatment of Locally Advanced or Metastatic Bladder Cancer of Variant Histology (United States)
- NCT07584499 · Phase 1 — Phase I Study of Becotatug Vedotin for Safety and Efficacy in EGFR-Positive Pediatric Relapsed/Refractory or Metastatic Solid Tumors (China)
- NCT07148050 · Phase 1 — Immunotherapy for Solid Tumor Malignancies in Pediatrics Using Interleukin-15 and -21 Armored Glypican-3-specific Chimeric Antigen Receptor T Cells (United States)
- NCT06198296 · Phase 1 — Immunotherapy For Adults With GPC3-Positive Solid Tumors Using IL-15 and IL-21 Armored GPC3-CAR T Cells (United States)
- NCT06242470 · Phase 1 — A Study of MGC026 in Participants With Advanced Solid Tumors (United States)
- NCT07244835 · Phase 1 — A Study of DEG6498 in Participants With Solid Tumors (China)
- NCT07195916 · Phase 1 — A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies (United States)
- NCT06942104 · Phase 1 — Imaging of Solid Tumors Using 18F-TRX (United States)
- NCT06349642 — Immune Checkpoint Inhibitor Response in Solid Tumors Using a Live Tumor Diagnostic Platform (United States)
- NCT01109394 — Comprehensive Omics Analysis of Pediatric and Adult Solid Tumors and Establishment of a Repository for Related Biological Studies (United States)
Most-relevant first: trials that name Renal Sarcoma, then broader trials you may still qualify for. 42 recruiting trials name this cancer on ClinicalTrials.gov. Eligibility is decided by each trial's team — bring these NCT numbers to your appointment.
Financial help to look into
- PAN Foundation — Copay assistance funds by diagnosis (funds open and close as money allows). https://www.panfoundation.org/
- HealthWell Foundation — Copay and premium assistance funds by disease. https://www.healthwellfoundation.org/
- CancerCare — financial assistance — Limited grants plus free financial counseling. https://www.cancercare.org/financial
- Family Reach — Help with everyday living costs (rent, transport, food) during treatment. https://familyreach.org/
- NeedyMeds — Searchable directory of drug patient-assistance and discount programs. https://www.needymeds.org/
Questions to ask your oncologist
- Of the open trials I found (for example NCT05770037), am I eligible for any — here or at a larger cancer center?
- What is my exact diagnosis — the type, subtype, stage, and grade?
- Has my tumor had molecular or genomic testing (e.g. next-generation sequencing), and what did it find?
- Should I have inherited (germline) genetic testing, and could it affect my treatment or my family?
- What is the goal of treatment for me — cure, long-term control, or comfort?
- What are all of my standard treatment options, and what does each one involve?
- What is the realistic benefit of each option, in actual numbers?
- What are the most common and the most serious side effects, and how are they managed?
- How will we know if treatment is working, and how often will I be scanned or tested?
- If the first treatment doesn't work, what are the next options?
- Are there gentler options if I want to prioritize quality of life?
- Am I eligible for any clinical trials — here or at a larger/academic cancer center?
- Is my case reviewed by a multidisciplinary tumor board?
- Would a second opinion at a center that treats my cancer often be worthwhile?
- Could any of my prescriptions, over-the-counter drugs, or supplements interfere with treatment?
- Which symptoms are emergencies, and who do I call after hours?
- Should I see palliative or supportive care alongside my treatment?
- How will treatment affect my daily life, work, and (if it matters to me) fertility?
- What can I safely do myself — diet and activity — and is anything I'm taking risky?
- What will treatment cost, and is financial assistance available?
- Should my tumor tissue be stored (biobanked) for future testing or trials?